Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

MNKD $0.55 0.0700 +14.58%
CASC $5.50 0.5300 +10.66%
BLCM $18.72 1.7400 +10.25%
SYRS $15.47 1.3900 +9.87%
CTIC $0.49 0.0430 +9.73%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

TRIL $6.70 -0.5000 -6.94%
MRTX $5.05 -0.2000 -3.81%
BPMC $27.01 -0.9900 -3.54%
RXDX $5.95 -0.2000 -3.25%
LBIO $6.00 -0.2000 -3.23%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Defining the True Value of Innovation in Cancer Treatment

(BMS) Oct 20, 2016 - Bristol-Myers Squibb believes the current structure of the Institute for Clinical and Economic Review’s (ICER) value assessment model takes a static approach to what is an incredibly dynamic environment. In ICER’s most recent evidence report on treatments for non-small cell lung cancer (NSCLC), we found fundamental issues that we believe stem from its severely flawed methodology.
read corporate press release 

Study: First-of-its-Kind Online Chemotherapy Approval Protocol Accelerates Cancer Patients' Access To Proven Treatments

(Nasdaq) Oct 20, 2016 - A study of a new web-based tool piloted with select medical oncology practices in UnitedHealthcare's care provider network in Florida found 99 percent of cancer patients received approval for chemotherapy drug regimens immediately or within 24 hours. The pilot also reduced cancer drug costs by 20 percent compared to UnitedHealthcare's cancer drug costs nationally, and all treatments were evidence-based and in alignment with the recommendations of the nation's leading cancer centers.
read article 

Scientists Build a Better Cancer Drug to Pass Through Blood-Brain Barrier

(Hopkins Medicine) Oct 20, 2016 - In efforts to develop new treatments for brain cancer, scientists from Johns Hopkins Drug Discovery and the Kimmel Cancer Center's Bloomberg~Kimmel Institute for Cancer Immunotherapy report they have altered the structure of an experimental drug that seems to enhance its ability to slip through the mostly impermeable blood-brain barrier
read press release 

Could Diet Change Help Treat Blood Cancer or Transplant Patients?

(Scientific American) Oct 20, 2016 - A team of researchers from California and Japan has found that an essential amino acid plays a crucial role in the creation of blood stem cells—a discovery the scientists say could offer a potential alternative to chemotherapy and radiation in treating blood cancer patients.
read article 

Sexual Pain in Women After Cancer Is Common, and Too Often Ignored

(UC Davis CCC) Oct 20, 2016 - Painful sex in women after cancer treatment is relatively common, often treatable and needs to be addressed by medical providers, a UC Davis oncologist and researcher suggests.
read press release 

Roots of Resistance to Cancer Drugs Run Deeper Than a Single Gene

(Yale Cancer Center) Oct 20, 2016 - Searching for more individual genes to predict responses to breast cancer therapy may not work, a new study suggests. Instead, scientists and clinicians need to pay attention to abnormalities in networks of genes, Yale researchers report in a paper published Oct. 20 in the journal Annals of Oncology.
read article 

More American Men with Early-Stage Prostate Cancer Could Opt Out of Immediate Treatment

(NYU Langone Medical Center) Oct 20, 2016 - A new report on Swedish men with non-aggressive prostate cancer suggests that a lot more American men could safely choose to monitor their disease instead of seeking immediate radiation treatment or surgery.
read press release 

CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial

(Yahoo! Finance) Oct 21, 2016 - CEL-SCI Corporation announced today: following up on our press release issued on September 26, 2016, we have received the Partial Clinical Hold letter from the U.S. Food and Drug Administration (FDA). CEL-SCI has started working on a response to the FDA and will work diligently with the FDA to seek to have the partial clinical hold lifted.
read article 

FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer

(StreetInsider) Oct 21, 2016 - Astellas Pharma Inc.and Pfizer Inc. today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for XTANDI® (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (CRPC) who were treated with enzalutamide compared to patients who were treated with bicalutamide.
read article 

Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early

(Merck) Oct 21, 2016 - Merck, known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).
read corporate press release 

Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients

(TheStreet) Oct 20, 2016 - Study met primary endpoint of non-inferiority versus zoledronic acid in delaying bone complications known as skeletal-related events.
read article 

Sanders Seeks Ariad Data On Cancer Drug Price Hikes

(STAT/Pharmalot blog) Oct 20, 2016 - Call it Bernie Sanders vs. Ariad Pharmaceuticals, Act Two.
read article 

CDC: Sexually Transmitted Disease Rates Are Rising

(USA Today) Oct 20, 2016 - The most commonly reported sexually transmitted diseases reached an all-time high in 2015, according to the annual Sexually Transmitted Disease Surveillance Report released Wednesday by the Centers for Disease Control and Prevention.
read article 

FDA Panel Backs Allergan's Drug for Frequent Nightly Urination

(Reuters) Oct 19, 2016 - The benefits associated with Allergan Plc's experimental drug to treat frequent nightly urination outweigh the risks for certain patients, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.
read article 

Stop Insurers From Making End Runs Around Patients With Preexisting Conditions

(STAT) Oct 19, 2016 - For years, insurers dropped sick people from their plans or denied coverage due to preexisting conditions like cancer, keeping them from the care and medicines they needed.
read article 

Rigel's Bleeding Disorder Drug Fails Late-stage Study

(Reuters) Oct 20, 2016 - Rigel Pharmaceuticals Inc said its bleeding disorder drug failed in a late-stage study, sending its shares down 37 percent in premarket trading on Thursday.
read article 

Madison Startup Advances Three-In-One Cancer Drug Rooted At UW

(University of Wisconsin-Madison) Oct 19, 2016 - The first target for Co-D is angiosarcoma, a rare and lethal cancer that arises from blood vessels.
read article 

Wearable Technology Is Improving Cancer Treatment One Day At A Time

(Forbes/Quora) Oct 19, 2016 - Researchers at the University of Southern California demonstrated how using wearable technology and smartphones can improve cancer treatment at a White House event that was held on October 3.
read article 

ASCO Chief Medical Officer Speaks About CancerLinQ™ Platform During ACS Clinical Congress Named Lecture

(ASCO in Action) Oct 19, 2016 - On October 19, ASCO Chief Medical Officer Richard L. Schilsky, MD, FACP, FASCO, gave the Commission on Cancer Oncology Lecture at the American College of Surgeons (ACS) Clinical Congress 2016.
read article 

CancerLinQ™ Platform Hits Milestone of Having More than One Million Patient Records in System

(ASCO) Oct 20, 2016 - CancerLinQ LLC, a wholly-owned nonprofit of the American Society of Clinical Oncology (ASCO), announced today that more than one million patient records are now in the CancerLinQ™ platform. In addition, 70 practices have signed agreements to participate in CancerLinQ, representing more than 1,500 oncologists.
read press release 

OPEN Pre-Conference Highlights

(ACCCBuzz) Oct 20, 2016 - We’re in St. Louis for the ACCC 33rd National Oncology Conference this week. Events got underway on Wednesday, October 19, with dynamic pre-conference sessions focused on some of the most challenging and rapidly evolving areas in cancer care delivery. Read on for highlights from the Oncology Pharmacy Education Network (OPEN) pre-conference.
read article 

Kite Pharma's CEO On Bringing Cancer-Killing T-cells To The FDA

(Forbes) Oct 20, 2016 - During a Q&A session with Wall Street analysts after Kite Pharma’s Investor Day on October 18 in New York, CEO Arie Belldegrun was thrilled when an audience member asked what the company has been doing to secure insurance reimbursement for KTE-C19, its experimental cancer treatment made from engineered immune cells called T-cells.
read article 

Medicare Subsidies May Help More Women Stick With Breast Cancer Drugs

( Oct 20, 2016 - Women on Medicare who get subsidies to help defray the cost of drugs may be less likely to stop taking hormone therapy for breast cancer than those who don't get financial assistance, a U.S. study suggests.
read press release 

Roche Revenue Gains as Sales of Breast Cancer Drugs Soar

(Bloomberg) Oct 20, 2016 - Roche Holding AG’s third-quarter revenue rose 4.5 percent as its trio of breast-cancer therapies offset stagnating sales of some of its older drugs.
read article 

TG Therapeutics, Inc. Announces the Launch of the Phase 1/2 Study of TGR-1202 and Carfilzomib in Patients with Relapsed or Refractory Lymphoma

(Yahoo! Finance) Oct 20, 2016 - TG Therapeutics, Inc. today announced the launch of a Phase 1/2 study to evaluate the safety and efficacy of TGR-1202, the Company's oral PI3K delta inhibitor in combination with carfilzomib, the FDA-approved proteasome inhibitor, in patients with relapsed or refractory lymphoma.
read article